Sharon M. Dial The activated clotting time (ACT) is a measurement of the activity of the intrinsic and common coagulation pathways. It measures the time from activation of the pathways by introduction of blood into a tube containing clot activator to the formation of fibrin strands that cause the blood to thicken when tilted. Patients that present with evidence of bleeding without previous trauma or prolonged bleeding with trauma should be evaluated for abnormalities in hemostasis. The ACT is especially useful to evaluate patients with evidence of a coagulation factor deficiency, either inherited or acquired. Clinical signs associated with coagulopathies include: In these patients, a quick assessment of clotting ability is warranted. The ACT test is a measure of the activity of the coagulation factors in the intrinsic pathway (Factors XII, XI, IX, and VIII) and the common pathway (Factors X, II, XIII, and V). It is much less sensitive than the activated partial thromboplastin time (APTT) and may not be prolonged unless there is a marked decrease in coagulation factor activity. Common coagulation abnormalities that can result in the prolongation of the ACT test include: Significant thrombocytopenia will result in a prolongation of the ACT test. A platelet count is advised before performing this test. If the platelet count is <10 000/μl, the ACT time will be affected. Equipment used for this test include:
11
Activated Clotting Time
11.1 Procedural Definition: (“What Is This Test About?”)
11.2 Procedural Purpose: Why Should I Perform This Test?
11.3 Equipment
11.4 Procedural Steps: How Do I Perform This Test?